"T'EMPUS EU/UK Requisition Form — 2025.02.11
Phone: +1800.739.4137 | Fax: +1800.893.0276 | support@tempus.com

A.PATIENT INFORMATION	ation is incomplete or n	lissing, testing	g mag be delaged.	•								
Last Name		MI First Name										
Lastivalie							i ii St Ivairie					
DOB (DD/MM/YYYY)	Medical Record # Biologi		Biological Sex							Phone		
Address (Street, Unit)			Г				Chata		Postal Code	Country		
Audiess (Sureet, Only)				City				State	Postar Code	Countr	y	
B.ORDERING PHYSICIAN INFORMATION												
Distributor				Ordering Physician (full legal name)						Phone		
Facility Name			Tempus	Tempus Account #			Email (required for report delivery)		Fax			
Facility Address (Street, Unit)			City	City			Postal C		ode		Country	
Additional person to be copied												
Name			Email/F	Email/Fax Facility Name								
Form completed by												
Name Email/Fax Facility Name												
C.TESTING OPTIONS												
Common test combinations Test do			ons			Specimen required			Optional add-on	tests (se	elect all that apply):	
		xT: 648-gene DNA sequencing test with no xR: whole transcriptome RNA sequencing t			atch;		FFPE Tiss	ue; llood or Saliva	Tissue Based Ad	d-Ons:	Algorithmic Add-Ons:	
Add xF liquid biopsy at time of order, based on the following: I believe it is medically necessary to order a liquid biopsy test concurrently with a solid tumor tissue test because of one or more of the of testing in this disease state; (b) turnaround time for tissue result may delay a treatment decision for my patient; (c) the tissue is at ri may not have a timely result to make at treatment decision for my patient; (d) genomic heterogeneity may cause the patient's available I want to make sure I have a complete mutation profile.							g reasons: (a) guidelir (e.g. small tissue, arcl	es support the use nived tissue) and I	PD-L1 IHC ¹ : 22C3 DEFAI 28-8 SP142	ULT	HRD ^{1,3} Tumor Origin (RNA) DPYD ¹ UGT1A1 ¹	
If I have not already ordered an xF test above, I opt to convert my xT solid tumor order to an xF liqui By converting immediately OR After an additional tissue request is attempted				uid biopsy test if necessary:					SP263 MMR IHC HER2 IHC + FISH ^{1,2}		1 See our Testing Resources website for IHC	
xT (DNA) & xR (RNA): Solid Tur		xT: 648-gene DNA sequencing test; xR: whole transcriptome test.			nscriptome R	NA sequencing FFPE Tissue			CLDN18 IHC FDA ²		and FISH tests ordered by cancer type, and Algorithmic Add-On logistics. 2 Powered by NeoGenomics.	
xE (DNA) & xR (RNA): Solid Tur	xE: over 19,000-gene whole exome DNA sequencing test wit xR: whole transcriptome RNA sequencing test.			ng test with r	normal mai		ïissue; I: Blood or Saliva			3 Normal sample is required for ovarian and breast cancers.		
Individual test options												
xR (RNA Only): Solid Tumor Whole transcriptome RNA				sequencing test. FFPE Tissue								
xT (DNA Only): Solid Tumor 648-gene DNA			DNA sequencing test. FFPE Tissue									
xF (Liquid Biopsy): OR xF+ (L	=+: 523-gene liquid bid	ne liquid biopsy test for solid tumors. Blood (Streck)										
xE (DNA Only): Solid Tumor/Normal Over 19,000-gene whole exome DNA sequencing test with normal match. FFPE Tissue; Normal: Blood or Saliva												
D.SPECIMEN RETRIEVAL See Tempus' specimen guidelines for collection instructions and further details.												
FFPE Tissue												
Option 1:	Option 3:				Pathology Lab (Name, City)							
Specific specimen requested	Option 2: Let the submitting pat choose specimen	thologist	•	y to be scheduled for:			Case Number Bloc		 <#		Date of Collection	
Blood		Saliva										
Sample previously submitted Date of Collection: Send saliva kit to patient Date of Collection:												
E.CURRENT DIAGNOSIS												
Breast NSCLC Colorectal Ovarian	Pancreatic Prostate	Other:		Primary	JICD-10 Co	odes (C &	D codes only)		Stage I	III IV	Other:	
Disease Status (select all that apply				Hasthe	patient ha	ad anu tu	oe of transplant?		Attachments			
Metastatic Relapse Other:				No	,		, ,		Copy of patient's progre		gress notes and/or medical records.	
Refractory Recurrent					Yes —Type: Copy of recent						logy report.	
F.BILLING INFORMATIO	N											
Primary Insurance Plan Name Policy #							Authorisation #		Policy Holder Name		Policy Holder DOB	
Patient Relationship to Policy Holder					Bill Type:					I.		
Self Spouse Child Other: Insurance Hospital/Institution Self pay/International												
G.PHYSICIAN SIGNATURE AND CONSENT												
I certify that the patient has received an explanation of the purpose, risks, and benefits of the ordered test(s). My signature certifies medical necessity of the test(s) (including that the test results will inform the treatment plan) and further certifies that I am authorized to order the test(s) and that the patient has provided informed consent that meets the requirements of applicable						Ordering Physician Signature						
law for Tempus or its reference lab to: (a) collect and use the patient's samples (including genetic m and perform the ordered test(s); (b) obtain, receive, and release health information (including test reimbursement or the processing of insurance claims (if applicable); and (c) collect, use, and retain obtained from the patient, all in accordance with the Tempus Consent to Genomic Testing form sig				results) as necessary for samples and information			Printed Name (full legal name)				Today's Date (DD/MM/YYYY)	
occamed normale patient, anniaccordance with the reinipus consent to Genomic resting form signed by the patient.										i e		